Show simple item record

dc.contributor.authorVan Wijmeersch, B
dc.contributor.authorBarone, D
dc.contributor.authorBroadley, S
dc.contributor.authorDive, D
dc.contributor.authorHupperts, RMM
dc.contributor.authorLycke, J
dc.contributor.authorMassacesi, L
dc.contributor.authorMontalban, X
dc.contributor.authorNaismith, RT
dc.contributor.authorPandey, K
dc.contributor.authorSchippling, S
dc.contributor.authorVermersch, P
dc.contributor.authorChung, L
dc.contributor.authorDaizadeh, N
dc.contributor.authoret al.
dc.description.abstractAims: Evaluate efficacy and safety of alemtuzumab over 6 y in patients who initiated alemtuzumab after receiving SC IFNB-1a in CARE-MS I. Methods: At investigator discretion, patients in TOPAZ can receive additional as-needed alemtuzumab (≥12 months apart; no criteria), or receive another DMT (at any time). MRI disease activity was defined as new gadolinium (Gd)-enhancing or new/enlarging T2 hyperintense lesions. Results: Of 139 patients initiating alemtuzumab in the extension, 117 (84%) completed Y2 of TOPAZ (Y6 after initiating alemtuzumab); 67% received neither additional courses of alemtuzumab nor another DMT. At Y6, the annualised relapse rate was 0.19, and 70% of patients had stable/improved EDSS scores from CARE-MS I baseline. After initiating alemtuzumab, 69% were free from 6-month confirmed disability worsening and 28% had 6-month confirmed disability improvement. At Y6, 62% were free of MRI disease activity, 82% were free of new Gd-enhancing lesions, and 62% were free of new/enlarging T2 hyperintense lesions. Median percent cumulative brain volume loss (BVL) from CARE-MS I baseline was -1.99% over 8 total study y; -1.49% occurred over Y0-2 with SC IFNB-1a, and -0.23% occurred over 6 y with alemtuzumab. Safety was consistent with the alemtuzumab arm of the core and extension studies. Conclusions: Alemtuzumab improved clinical, MRI, and BVL outcomes in patients who initiated alemtuzumab after receiving SC IFNB-1a in CARE-MS I. These improved outcomes were maintained over 6 y in the absence of continuous treatment, with a consistent safety profile that is manageable and acceptable.en_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofconferencename34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)en_US
dc.relation.ispartofconferencetitleMultiple Sclerosis Journalen_US
dc.relation.ispartoflocationBerlin, Germanyen_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsClinical Neurologyen_US
dc.subject.keywordsNeurosciences & Neurologyen_US
dc.titleAlemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)en_US
dc.typeConference outputen_US
dc.type.descriptionE3 - Conferences (Extract Paper)en_US
dcterms.bibliographicCitationVan Wijmeersch, B; Barone, D; Broadley, S; Dive, D; Hupperts, RMM; Lycke, J; Massacesi, L; Montalban, X; Naismith, RT; Pandey, K; Schippling, S; Vermersch, P; Chung, L; Daizadeh, N; et al., Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study), Multiple Sclerosis Journal, 2018, 24, pp. 488-489en_US
gro.hasfulltextNo Full Text
gro.griffith.authorBroadley, Simon

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record